Results 51 to 60 of about 5,550 (180)

JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia [PDF]

Leukemia, 2006
N ...
Zecca, M, Bergamaschi, G, Kratz, C, Bergsträßer, E, Danesino, C, De Filippi, P, Hasle, H, Lisini, D, Locatelli, F, Pession, A, Sainati, L, Starý, J, Trebo, M, van den Heuvel-Eibrink, M, Wójcik, D, Niemeyer, C M, NA, NA   +16 more
openaire   +6 more sources

Infrequent V617F mutation of the JAK2 gene in myeloid leukemia and its absence in lymphoid malignancies in Japan

Genetics and Molecular Biology, 2008
A unique mutation of the JAK2 gene, V617F, has recently been identified in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis.
Naoki Mori, Kentaro Yoshinaga, Makiko Tada, Yanhua Wang, Masayuki Shiseki, Toshiko Motoji   +5 more
doaj   +1 more source

Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant. [PDF]

PLoS ONE, 2013
The acquired mutation (V617F) of Janus kinase 2 (JAK2) is observed in the majority of patients with myeloproliferative neoplasms (MPNs). In the screening of genes whose expression was induced by JAK2 (V617F), we found the significant induction of c-Myc ...
Megumi Funakoshi-Tago, Kazuya Sumi, Tadashi Kasahara, Kenji Tago   +3 more
doaj   +1 more source

Leukemic blasts in transformed JAK2-V617F–positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Blood, 2007
To study the role of the JAK2-V617F mutation in leukemic transformation, we examined 27 patients with myeloproliferative disorders (MPDs) who transformed to acute myeloid leukemia (AML). At MPD diagnosis, JAK2-V617F was detectable in 17 of 27 patients.
Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, Talmant P, Tichelli A, Hermouet S, Skoda RC   +9 more
openaire   +3 more sources

Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera. [PDF]

PLoS ONE, 2011
BACKGROUND: JAK2 V617F, a somatic point mutation that leads to constitutive JAK2 phosphorylation and kinase activation, has been incorporated into the WHO classification and diagnostic criteria of myeloid neoplasms.
Zhiyuan Wu, Hong Yuan, Xinju Zhang, Weiwei Liu, Jinhua Xu, Wei Zhang, Ming Guan   +6 more
doaj   +1 more source

IL-4 Serum Level Estimation in Myeloproliferative Neoplasm Patients

مجلة مركز بحوث التقنيات الاحيائية, 2022
Back Ground: Myeloproliferative neoplasm (MPN) is a long-term blood disease that has an excess production of mature hematopoietic pluripotent stem cells in the bone marrow. In the early fifties, W.
Ahmed Rushdi Abdullah
doaj   +1 more source

Inhibitory HLA‐C/KIR2DL2 Interactions and KIR Allelic Polymorphisms Are Associated With Susceptibility to Philadelphia Chromosome‐Negative Myeloproliferative Neoplasms

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background Immune surveillance is increasingly recognized as a determinant of clonal selection in Philadelphia chromosome‐negative myeloproliferative neoplasms (MPN). While HLA‐restricted adaptive immune effects have been described, the contribution of inherited variation in natural killer (NK)‐cell regulatory pathways remains less well ...
Velizar Shivarov, Gergana Tsvetkova, Evgueniy Hadjiev, Milena Ivanova   +3 more
wiley   +1 more source

Immune Effector Cell‐Associated Hematotoxicity With Secondary Myelofibrosis Following Idecabtagene‐Vicleucel for Multiple Myeloma, Comprehensively Treated With Autologous Hematopoietic Stem Cell Boosting

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Pancytopenia accompanied by chimeric antigen receptor T cell (CAR‐T) therapy is termed immune effector cell‐associated hematopoietic toxicity (ICAHT), which is often sustained and refractory to supportive care. We report a case of a 52‐year‐old man with multiple myeloma who developed severe ICAHT with secondary myelofibrosis (sMF) after ...
Keishi Ogura, Takahiro Fujino, Takahisa Nakamura, Akihiro Miyashita, Akio Onishi, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Shinichi Fuchida, Junya Kuroda   +9 more
wiley   +1 more source

The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms

Hematology/Oncology and Stem Cell Therapy, 2015
CONTEXT AND OBJECTIVE: By using molecular markers, it is possible to gain information on both the classification and etiopathogenesis of chronic myeloproliferative neoplasias (MPN). METHODS: In a group of 27 Mexican mestizo patients with MPNs, we studied
Nancy Labastida-Mercado, Samantha Galindo-Becerra, Javier Garcés-Eisele, Perla Colunga-Pedraza, Valeria Guzman-Olvera, Virginia Reyes-Nuñez, Guillermo J Ruiz-Delgado, Guillermo J Ruiz-Argüelles   +7 more
doaj   +1 more source

“Intrapericardial Approach” for Venous Outflow Reconstruction in Living‐Donor Liver Transplantation for Budd‐Chiari Syndrome: Surgical Techniques and LongTerm Outcomes

Annals of Gastroenterological Surgery, Volume 10, Issue 4, Page 1356-1364, July 2026.
Unlike deceased‐donor liver transplantation, living‐donor liver transplantation (LDLT) for Budd‐Chiari Syndrome (BCS) presents distinctive challenges in hepatic venous (HV)‐outflow reconstruction because diseased HV–inferior vena cava (IVC) cannot be entirely replaced with healthy donor vessels.
Koichiro Hata, Tetsuya Tajima, Satoshi Ogiso, Shinji Uemoto, Etsuro Hatano   +4 more
wiley   +1 more source